Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and Quality Assurance
September 29, 2016 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today...
Epizyme Establishes Collaboration with Foundation Medicine to Support Tazemetostat Phase 2 Clinical Trial
September 21, 2016 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the...
Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development with First-in-Class PRMT5 Inhibitor
September 15, 2016 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a...
Epizyme to Present at Upcoming Investor Conferences
September 01, 2016 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company...
Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma
August 11, 2016 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the first...
Epizyme Announces Second Quarter 2016 Financial Results and Progress Against Corporate Objectives
August 08, 2016 06:30 ET
|
Epizyme, Inc.
Company Updates Financial Guidance Extending Runway into At Least Second Quarter of 2018 Conference Call to Be Held Today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE...
Epizyme to Report Second Quarter 2016 Financial Results on August 8, 2016 and Participate in Upcoming Wedbush PacGrow Healthcare Conference
August 01, 2016 16:05 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced today that...